Results 51 to 60 of about 6,463,095 (311)

Time-to-progression, time-to-local progression, progression-free-survival and overall survival after TACE among groups.

, 2018
Time-to-progression, time-to-local progression, progression-free-survival and overall survival after TACE among groups.
Han Chu Lee (154230), Danbi Lee (3682918), Yung Sang Lee (481493), Jihyun An (2232697), Young-Hwa Chung (129517), Seong Kyun Na (5349014), Yong Moon Shin (4164724), Gwang Hyeon Choi (5349011), Ju Hyun Shim (481492), Kang Mo Kim (154235), Young-Suk Lim (388118)   +10 more
core   +1 more source

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman, Deborah Meyran, Vajiranee Malalasekera, Heather Weerdenburg, Janine Campbell, Rachel Conyers, Stacie Wang, Hannah Walker, Seong Lin Khaw, Diane Hanna   +9 more
wiley   +1 more source

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study

Cancer Management and Research, 2014
Yiyun Tang,1 Paul Bycott,1 Örjan Åkerborg,2 Linus Jönsson,2 Sylvie Negrier,3 Connie Chen4 1Pfizer Global Research and Development, La Jolla, CA, USA; 2OptumInsight, Stockholm, Sweden; 3Medical Oncology Department, University of Lyon, Lyon,
Tang Y, Bycott P, Åkerborg Ö, Jönsson L, Negrier S, Chen C   +5 more
doaj  

The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.

BMC Cancer
Introduction The persistent challenge of temozolomide (TMZ) resistance and the eventual recurrence of tumors underscore the need for ongoing research and the development of novel therapeutic strategies.
Made Agus Mahendra Inggas, Utsav Patel, Jeremiah Hilkiah Wijaya, Nina Otinashvili, Vyshnav Rajagopal Menon, Abhay Krishnan Iyer, Tawfiq Turjman, Surbhi Dadwal, Mari Gadaevi, Azada Ismayilova, Shiva Jashwanth Gaddam, Prakriti Arya, Nihar Upadhyay, Saurabh Kataria   +13 more
doaj   +1 more source

Progression-free survival according to BMI status at baseline.

, 2018
Progression-free survival according to BMI status at baseline.
Ji Kon Ryu (481706), Jun Hyuk Son (2921766), Woo Hyun Paik (481705), Jae Woo Lee (2072779), Young Hoon Choi (2725033), Sang Hyub Lee (5047862), Yong-Tae Kim (249037), Jinwoo Kang (5047865), Jin Ho Choi (3852334)   +8 more
core   +1 more source

Chemotherapy for Spinal Cord Intramedullary Pediatric Low‐Grade Glioma—A Systematic Literature Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric intramedullary low‐grade gliomas (PIMLGGs) are rare neoplasms that present unique clinical and management challenges. Although surgery remains the primary tool for tissue diagnosis and decompression, complete gross‐total resection is frequently unfeasible due to the infiltrative nature of these lesions.
Olga M. Sergeenko, Segev Gabay, Jonathan Roth, Amit Ringel, Rina Dvir, Shlomi Constantini   +5 more
wiley   +1 more source

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Journal of Cardiothoracic Surgery
Background Durvalumab supplementation may have some potential in improving the efficacy in patients with non-small-cell lung cancer (NSCLC), and this meta-analysis aims to explore the impact of durvalumab supplementation on efficacy for NSCLC.
Chengchen Wang, Hongyi Fu, Feng Wang
doaj   +1 more source

Progression-free survival curve of the 13 patients.

, 2018
The 5-year progression-free survival rate was 63.5%.
Yifei Wang (95207), Tao Ji (1313499), Wei Guo (86150), Zhongyan Chen (1883233), Ran Wei (295560)   +4 more
core   +1 more source

CHALLENGES AND METHODOLOGIES IN USING PROGRESSION FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN ONCOLOGY [PDF]

International Journal of Technology Assessment in Health Care, 2018
Objectives:A primary outcome in oncology trials is overall survival (OS). However, to estimate OS accurately requires a sufficient number of patients to have died, which may take a long time. If an alternative end point is sufficiently highly correlated with OS, it can be used as a surrogate.
Hernandez-Villafuerte, K., Fischer, A., Latimer, N.R.   +2 more
openaire   +3 more sources

Progression and Free Progression Survival Indices in Patients with Multiple Myeloma

Medico Legal Update, 2021
The main feature in multiple myeloma is osteolysis and, hence, bone turnover markers have got the at mostcare in different studies on this disease. The present paper would stress on the calculation of free progressionsurvival indices using some of these markers .Sixty-five MM (males=41, females=24) patients distributed to different hematologycenters in
null Sadik A. Abdullah, null Waseem F. Al-Tameemi, null Ghassan A.A. Al-Shamma   +2 more
openaire   +2 more sources